{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-003321","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.650658+00:00","generated_at":"2026-05-16T10:34:04.370714+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Glaukos reports preliminary Q4 2025 net sales ~$143M (+36% YoY); reaffirms FY2026 guidance $600-620M","bullets":["Q4 2025 net sales ~$143M (+36% YoY); FY2025 net sales ~$507M (+32% YoY).","U.S. Glaucoma net sales FY2025 $299M, including iDose TR $136M; Corneal Health $86M.","Cash & equivalents $283M, no debt at Q4 end; 2026 revenue guidance reaffirmed $600-620M.","International Glaucoma net sales FY2025 $122M; Q4 alone ~$33M.","Company will report full Q4 & FY2025 results on Feb 17, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-003321","json":"https://secwatch.observer/filing/0001104659-26-003321.json","markdown":"https://secwatch.observer/filing/0001104659-26-003321.md","text":"https://secwatch.observer/filing/0001104659-26-003321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000110465926003321/0001104659-26-003321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000110465926003321/gkos-20260113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:34:04.370714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}